Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.

ESMO Open · 2020 · PMC7440698 · PMID 32817130

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Overall, the rate of successful resections in the pamrevlumab treated group 8/24 (33%) was higher than in the control group 1/13 (8%) but this did not reach statistical significance, most probably due to small sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.